They speculated that the inefficacy of IDO inhibitors in human cancer clinical trials was due to tissue levels of kynurenine and its derivatives that were too low to act as a major metabolic barrier to anti-tumor immunity. The gene discussed is IDO1; the disease is neoplasm.